Pfizer to Sell About $3.25 Billion Stake in Sensodyne-Maker Haleon, Bookrunner Says
(Reuters) - Pfizer intends to offload about 540 million shares in the British consumer healthcare company Haleon, a bookrunner said on Monday. The proposed sale will reduce the top shareholder's interest in Sensodyne-maker Haleon to 16.2% from 22.6%.
Following a similar move in March, Pfizer is offloading another tranche of Haleon shares. | Pfizer has sold 640 million ...
Haleon, a global leader in consumer health, today announced the appointment of Christine Jakovcic as General Manager, Haleon ...
In a report released today, Guillaume Delmas from UBS maintained a Buy rating on Haleon PLC (HLN – Research Report), with a price target ...
DRL's Swiss subsidiary completed the acquisition through the purchase of shares of Northstar Switzerland SARL, a Haleon group ...
Pfizer Inc. plans to sell 540 million worth of shares in Haleon Plc, as it pares back its holding in the UK consumer health ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback